SI3230316T1 - Zdravljenje starostne degeneracije makule z majhno aktivno horoidalno neovaskularizacijsko lezijo - Google Patents
Zdravljenje starostne degeneracije makule z majhno aktivno horoidalno neovaskularizacijsko lezijoInfo
- Publication number
- SI3230316T1 SI3230316T1 SI201531805T SI201531805T SI3230316T1 SI 3230316 T1 SI3230316 T1 SI 3230316T1 SI 201531805 T SI201531805 T SI 201531805T SI 201531805 T SI201531805 T SI 201531805T SI 3230316 T1 SI3230316 T1 SI 3230316T1
- Authority
- SI
- Slovenia
- Prior art keywords
- treatment
- macular degeneration
- related macular
- choroidal neovascularization
- age related
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/093548 WO2016090590A1 (en) | 2014-12-11 | 2014-12-11 | Treatment of age related macular degeneration with a small active choroidalneovascularizationlesion |
| CN2015089251 | 2015-09-09 | ||
| PCT/US2015/065022 WO2016094673A1 (en) | 2014-12-11 | 2015-12-10 | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion |
| EP15819965.3A EP3230316B1 (en) | 2014-12-11 | 2015-12-10 | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3230316T1 true SI3230316T1 (sl) | 2022-05-31 |
Family
ID=55069121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201531805T SI3230316T1 (sl) | 2014-12-11 | 2015-12-10 | Zdravljenje starostne degeneracije makule z majhno aktivno horoidalno neovaskularizacijsko lezijo |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20170326106A1 (https=) |
| EP (2) | EP3985023A1 (https=) |
| JP (3) | JP7320919B2 (https=) |
| CN (3) | CN114306575A (https=) |
| AU (4) | AU2015360496B2 (https=) |
| CA (1) | CA2970315C (https=) |
| DK (1) | DK3230316T3 (https=) |
| ES (1) | ES2907148T3 (https=) |
| HR (1) | HRP20220066T1 (https=) |
| HU (1) | HUE057653T2 (https=) |
| LT (1) | LT3230316T (https=) |
| PL (1) | PL3230316T3 (https=) |
| PT (1) | PT3230316T (https=) |
| RS (1) | RS62827B1 (https=) |
| SI (1) | SI3230316T1 (https=) |
| WO (1) | WO2016094673A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007237096C1 (en) | 2006-04-07 | 2012-12-13 | EyePoint, Inc. | Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof |
| AU2012323856B2 (en) | 2011-10-13 | 2017-05-25 | EyePoint, Inc. | Methods for treating Vascular Leak Syndrome and cancer |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| PT3230316T (pt) | 2014-12-11 | 2022-02-24 | Bayer Healthcare Llc | Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa |
| US10525035B2 (en) * | 2014-12-18 | 2020-01-07 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of retinopathy and other ocular diseases |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| CN111699004A (zh) * | 2018-02-06 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| US11103552B2 (en) | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
| CN120058958A (zh) | 2018-09-24 | 2025-05-30 | 视点制药公司 | 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体 |
| EP3873519A1 (en) | 2018-10-29 | 2021-09-08 | F. Hoffmann-La Roche AG | Antibody formulation |
| CN118718181A (zh) | 2019-06-05 | 2024-10-01 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US11944663B2 (en) * | 2020-06-18 | 2024-04-02 | Chengdu Kanghong Biotechnologies Co. Ltd. | Method for treating angiogenic eye disorders using VEGF antagonists |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2025047970A1 (ja) * | 2023-08-31 | 2025-03-06 | 国立大学法人京都大学 | 光感受性物質含有リポタンパク質、光線力学的療法用製剤、薬物デリバリー方法及び後眼部新生血管閉塞方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69735292T2 (de) | 1996-10-25 | 2006-10-19 | Gilead Sciences, Inc., Foster City | Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe |
| JP3957765B2 (ja) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | 抗ｖｅｇｆ抗体 |
| CN100523187C (zh) | 1999-06-08 | 2009-08-05 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| US8034803B2 (en) * | 2001-02-06 | 2011-10-11 | Qlt Inc. | Photodynamic therapy of occult age-related macular degeneration |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| KR20260004598A (ko) * | 2011-01-13 | 2026-01-08 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| PT3230316T (pt) | 2014-12-11 | 2022-02-24 | Bayer Healthcare Llc | Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa |
-
2015
- 2015-12-10 PT PT158199653T patent/PT3230316T/pt unknown
- 2015-12-10 EP EP21207057.7A patent/EP3985023A1/en active Pending
- 2015-12-10 HR HRP20220066TT patent/HRP20220066T1/hr unknown
- 2015-12-10 WO PCT/US2015/065022 patent/WO2016094673A1/en not_active Ceased
- 2015-12-10 PL PL15819965T patent/PL3230316T3/pl unknown
- 2015-12-10 JP JP2017530277A patent/JP7320919B2/ja active Active
- 2015-12-10 CN CN202210019267.XA patent/CN114306575A/zh active Pending
- 2015-12-10 CN CN201580066980.8A patent/CN106999511A/zh active Pending
- 2015-12-10 RS RS20220058A patent/RS62827B1/sr unknown
- 2015-12-10 EP EP15819965.3A patent/EP3230316B1/en active Active
- 2015-12-10 ES ES15819965T patent/ES2907148T3/es active Active
- 2015-12-10 DK DK15819965.3T patent/DK3230316T3/da active
- 2015-12-10 SI SI201531805T patent/SI3230316T1/sl unknown
- 2015-12-10 AU AU2015360496A patent/AU2015360496B2/en active Active
- 2015-12-10 CN CN202110181096.6A patent/CN112826934A/zh active Pending
- 2015-12-10 CA CA2970315A patent/CA2970315C/en active Active
- 2015-12-10 HU HUE15819965A patent/HUE057653T2/hu unknown
- 2015-12-10 US US15/534,030 patent/US20170326106A1/en not_active Abandoned
- 2015-12-10 LT LTEPPCT/US2015/065022T patent/LT3230316T/lt unknown
-
2019
- 2019-06-26 US US16/453,242 patent/US20190381008A1/en active Pending
-
2020
- 2020-10-15 JP JP2020173951A patent/JP2021004262A/ja active Pending
-
2021
- 2021-10-08 AU AU2021107575A patent/AU2021107575A4/en not_active Expired
- 2021-10-08 AU AU2021245214A patent/AU2021245214B2/en active Active
-
2022
- 2022-09-26 JP JP2022152791A patent/JP2022183183A/ja active Pending
-
2024
- 2024-07-31 AU AU2024205237A patent/AU2024205237A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021245214B2 (en) | 2024-05-02 |
| CA2970315A1 (en) | 2016-06-16 |
| ES2907148T3 (es) | 2022-04-22 |
| CN106999511A (zh) | 2017-08-01 |
| HUE057653T2 (hu) | 2022-05-28 |
| EP3230316B1 (en) | 2022-01-05 |
| AU2015360496A1 (en) | 2017-05-25 |
| AU2021245214A1 (en) | 2021-11-04 |
| PL3230316T3 (pl) | 2022-05-02 |
| RS62827B1 (sr) | 2022-02-28 |
| US20170326106A1 (en) | 2017-11-16 |
| HRP20220066T1 (hr) | 2022-04-15 |
| LT3230316T (lt) | 2022-02-10 |
| US20190381008A1 (en) | 2019-12-19 |
| JP7320919B2 (ja) | 2023-08-04 |
| AU2024205237A1 (en) | 2024-08-22 |
| DK3230316T3 (da) | 2022-03-28 |
| EP3230316A1 (en) | 2017-10-18 |
| JP2017537117A (ja) | 2017-12-14 |
| JP2021004262A (ja) | 2021-01-14 |
| EP3985023A1 (en) | 2022-04-20 |
| AU2021107575A4 (en) | 2022-01-06 |
| CN112826934A (zh) | 2021-05-25 |
| CN114306575A (zh) | 2022-04-12 |
| CA2970315C (en) | 2023-08-22 |
| PT3230316T (pt) | 2022-02-24 |
| JP2022183183A (ja) | 2022-12-08 |
| WO2016094673A1 (en) | 2016-06-16 |
| AU2015360496B2 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3230316T1 (sl) | Zdravljenje starostne degeneracije makule z majhno aktivno horoidalno neovaskularizacijsko lezijo | |
| IL265497B (en) | Methods for treating eye diseases | |
| IL252159B (en) | Methods and formulations for the treatment of diseases of the blood vessels of the eye | |
| IL253244A0 (en) | Methods for treating retinal diseases | |
| GB201403260D0 (en) | Treatment of retinal degeneration using gene therapy | |
| HUE041940T2 (hu) | MRNS-terápia szembetegségek kezelésére | |
| IL246791A0 (en) | Compositions and methods for treating eye diseases | |
| PT3658140T (pt) | Combinações de aprocitentan com outros ingredientes ativos para o tratamento de hipertensão resistente | |
| EP3122782A4 (en) | Compositions and methods for treatment of diabetic macular edema | |
| PL2953596T3 (pl) | Technika fotodysrupcyjnej, wieloimpulsowej obróbki materiału | |
| IL239736A0 (en) | New pitfalls in the treatment of macular degeneration | |
| ZA201704793B (en) | Treatment of retinal degeneration using progenitor cells | |
| SG11201607996SA (en) | Effect of lipophilic nutrients on diabetic eye diseases | |
| EP3089748A4 (en) | Treating ocular neovascularization | |
| SG11201608257RA (en) | A device for a medical treatment of a sclera | |
| IL247116A0 (en) | Compositions and methods for treating and preventing macular degeneration | |
| SI3509541T1 (sl) | Leče za intrastromalno implantacijo roženice | |
| EP3213762A4 (en) | Novel treatment of cornea using laminin | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| PL3233174T3 (pl) | Wewnątrzgałkowe dostarczanie bioaktywnych cząsteczek za pomocą jontoforezy | |
| IL261891A (en) | Active retinal implant | |
| IL252394A0 (en) | Methods for preventing, reducing or treating macular degeneration | |
| HK1230941A1 (en) | Treating ocular neovascularization | |
| GB201413330D0 (en) | Agricultural treatment | |
| GB201400839D0 (en) | Agricultural treatment |